New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
12:24 EDTGME, RS, CFX, BIIB, MUSA, CHRW, MSFT, ELN, BIOL, SFLY, TWX, ZNGA, DIS, AFL, RLOn The Fly: Midday Wrap
The Wall Street averages were nearly unchanged at midday in a session of relative calm and consolidation following three straight days in which the Dow experienced triple digit moves... ECONOMIC EVENTS: In the U.S. the economic calendar was light, though the Department of Energy did report that crude supplies grew by 2.62M barrels, roughly in-line with forecasts. In Japan, the governor of its central bank offered to step down three weeks before the end of his term, fueling speculation that accelerated and more aggressive stimulus measures may follow and sparking a 3.8% run-up in the Nikkei average. In Europe, German industrial orders climbed 0.8% in December as demand from the euro zone rebounded... COMPANY NEWS: Dow component Walt Disney (DIS) rose 1% after reporting quarterly earnings and revenue that beat analyst estimates. Among others reporting last night and this morning, Time Warner (TWX), Ralph Lauren (RL), Zynga (ZNGA) and Shutterfly (SFLY) advanced, while Aflac (AFL), C.H. Robinson (CHRW) and Colfax (CFX) declined... MAJOR MOVERS: Among the notable gainers were BIOLASE (BIOL), which rose 31% after receiving FDA clearance for a soft tissue laser device, and Metals USA (MUSA), which gained 13% after agreeing to be acquired by Reliance Steel (RS) for $20.65 per share. Among the noteworthy losers was Elan (ELN), which fell 9% after agreeing to sell its 50% interest in the Tysabri MS drug to Biogen (BIIB) for $3.25B in cash and future royalty payments. Also lower were shares of GameStop (GME), which slid nearly 7% following a report suggesting the next version of Microsoft's (MSFT) Xbox system will not allow used games to be resold... INDICES: Near noon, the Dow was down 2.26, or 0.02%, to 13,977.04; the Nasdaq was up 2.39, or 0.08%, to 3,173.97; and the S&P 500 was up 0.92, or 0.06%, to 1,512.21.
News For DIS;TWX;RL;ZNGA;SFLY;AFL;CHRW;CFX;BIOL;MUSA;RS;ELN;BIIB;GME;MSFT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
July 22, 2015
16:27 EDTMSFTOn The Fly: Top stock stories for Wednesday
Stocks began the session in negative territory and remained there throughout the day. Uninspiring earnings reports from Apple (AAPL) and Microsoft (MSFT) were enough to push the Nasdaq lower and the rest of the market followed. There was good news on the housing sector, with both existing home sales and a housing market index coming in with good data, but it was not enough to overcome the tech selloff. ECONOMIC EVENTS: In the U.S., the FHFA home price index rose 0.4% to 222.8 in May, as expected. Existing home sales rose 3.2% to a 5.49M rate in June, better than the 0.9% increase that was expected. In Europe, the European Central Bank reportedly raised the cap on Greece's Emergency Liquidity Assistance by EUR900M to EUR90.4B, according to Bloomberg. COMPANY NEWS: Shares of Apple dropped $5.79, or 4.43%, to $124.96 after iPhone shipments in the just completed quarter and the company's sales forecast for the new quarter missed estimates. A number of suppliers to Apple declined in tandem with the tech giant. Skyworks Solutions (SWKS), Qorvo (QRVO) and NXP Semiconductors (NXPI) were among the many semiconductor stocks that slid following Apple's report... Microsoft declined $1.88, or 3.97%, to $45.40 after reporting its Q4 Devices and Consumer revenue declined 13% and its Windows OEM revenue decreased 22% as revenue was impacted by PC market declines following the XP end-of-support refresh cycle. MAJOR MOVERS: Among the notable gainers was Thoratec (THOR), which rose $5.84, or 10.14% to $63.42 after St. Jude Medical (STJ) announced an agreement to acquire the company for $63.50 per share in a transaction valued at $3.4B. Shares of St. Jude, meanwhile, edged down by 4c to $76.67. Also higher following earnings reports were shares of Intuitive Surgical (ISRG) and Chipotle Mexican Grill (CMG), advancing about 8.5% and 7.8%, respectively. Among the noteworthy losers was Caesars Entertainment (CZR), which dropped $3.26, or 40.65%, to $4.76 following reports that a judge ruled the company must face certain creditor lawsuits that could force a bankruptcy. Caesars Acquisition (CACQ) also dipped after the news, falling $1.13, or 14.52%, to $6.65. Also lower was XOMA (XOMA), which plummeted $3.46, or 78.61%, to 94c and saw downgrades at numerous research firms after the company's Phase 3 gevokizumab study did not meet its primary endpoint. INDEXES: The Dow fell 65.60, or 0.37%, to 17,853.69, the Nasdaq lost 36.35, or 0.7%, to 5,171.77, and the S&P 500 declined 5.06, or 0.24%, to 2,114.15.
15:02 EDTMSFTOptions Update; July 22, 2015
Subscribe for More Information
13:06 EDTMSFTCompetitors ask EU to probe Google ad technology market practices, FT says
Several of Google's (GOOG) rivals, including OpenX and AppNexus, which is part owned by WPP (WPPGY) and Microsoft (MSFT), have suggested that the European Union investigate the internet giant, claiming it may be unlawfully stifling competition in the market for advertising technology, the Financial Times reports. The companies' grievances relate to the way in which Google bundles its advertising technology products through contracts that may discourage or even prevent customers from using competitors' services, the report says. The companies in question have submitted documents to the EU expressing concern over the issue but have not submitted an official complaint, the report adds. Reference Link
12:32 EDTMSFTOn The Fly: Top stock stories at midday
Stocks on Wall Street were lower at midday as slides in a number of big name tech stocks following their earnings reports dominated the news flow and largely dictated the market's direction. ECONOMIC EVENTS: In the U.S., the FHFA home price index rose 0.4% to 222.8 in May, as expected. Existing home sales rose 3.2% to a 5.49M rate in June, better than the 0.9% increase that was expected. In Europe, the European Central Bank reportedly raised the cap on Greece's Emergency Liquidity Assistance by EUR900M to EUR90.4B, according to Bloomberg. COMPANY NEWS: The tech sector has been weak, headlined of course by a 5% pullback in shares of Apple (AAPL) after iPhone shipments in the just completed quarter and the company's sales forecast for the new quarter missed estimates. Adding to the negative tone in tech stocks, and contributing further to the decline in the Nasdaq, was the 3% drop seen in Microsoft (MSFT) shares after its quarterly report as well as Yahoo's (YHOO) 1% decline after its revenue outlook missed the consensus forecast... Shares of Boeing (BA) and Coca-Cola (KO) fared better than Dow peer Apple after each reported better than expected sales and profits, though neither stock was moving far from where they closed yesterday's trading. MAJOR MOVERS: Among the notable gainers was Thoratec (THOR), which rose 10% after the company agreed to be acquired by St. Jude Medical (STJ) for $3.4 billion in cash, or $63.50 per share. St. Jude shares advanced fractionally after the deal, which had been foreshadowed by media reports yesterday, was announced. Also higher following their earnings reports were Intuitive Surgical (ISRG), which gained 10%, Chipotle Mexican Grill (CMG), which advanced 8% and Whirlpool (WHR), which was up 6%. Among the noteworthy losers were a number of suppliers to Apple that declined in tandem with the tech giant after it reported a sequential drop in iPhone sales. Skyworks Solutions (SWKS), Cirrus Logic (CRUS), Qorvo (QRVO) and NXP Semiconductors (NXPI) were among the many semiconductor stocks that slid following Apple's report. Also sharply lower was antibody-based therapeutics maker XOMA (XOMA), which plunged more than 73% and was downgraded to Neutral at Piper Jaffray after a Phase III trial of its gevokizumab drug in patients with Behcet's disease uveitis did not meet its primary endpoint. INDEXES: Near midday, the Dow was down 82.22, or 0.46%, to 17,837.07, the Nasdaq was down 42.68, or 0.82%, to 5,165.44, and the S&P 500 was down 6.93, or 0.33%, to 2,112.28.
12:27 EDTTWX, DISTime Warner's HBO lands sports commentator Bill Simmons
Subscribe for More Information
12:21 EDTTWX, DISTime Warner's HBO announces multiyear deal with Bill Simmons
Bill Simmons left Disney's (DIS) ESPN earlier this year.
10:59 EDTBIIBBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:01 EDTBIIBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTMSFTActive equity options trading on open:
Subscribe for More Information
09:28 EDTBIIBBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
09:22 EDTBIIBBiogen downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:19 EDTMSFTBofA/Merrill says Microsoft battling license declines with Cloud and Hardware
Subscribe for More Information
09:07 EDTMSFT, BIIBOn The Fly: Pre-market Movers
Subscribe for More Information
07:55 EDTMSFTMicrosoft shares should be bought on weakness, says RBC Capital
Subscribe for More Information
07:45 EDTMSFTMicrosoft shares still have downside, says Citi
Subscribe for More Information
07:19 EDTBIIBBiogen drops 4.8% to $390 after reporting Alzheimer's drug data
07:12 EDTMSFTMicrosoft hurdles remain but still an attractive story, says UBS
Subscribe for More Information
06:50 EDTBIIBBiogen's Alzheimer's candidate shows reduction of clinical decline
Subscribe for More Information
05:55 EDTMSFTQualcomm to cooperate with Microsoft, Allwinner in mobile market, DigiTimes says
Qualcomm (QCOM) is expected to ramp up its penetration in the entry-level mobile device market by cooperating with Microsoft (MSFT) to launch low-cost Windows Mobile 10 products, reports DigiTimes Research. Qualcomm is also expected to cooperate with Allwinner Technology to launch 3G/4G solutions for connected tablets. Reference Link
05:50 EDTMSFTMicrosoft price target lowered to $37 from $39 at Jefferies
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use